Dr. Vikram M. Atit, MD
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Years since graduation
- 35
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 667
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
FL license ME0071634
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Morton Plant Hospital Clearwater, FL
- Mease Countryside Hospital Safety Harbor, FL
- Mease Dunedin Hospital Dunedin, FL
- Adventhealth North Pinellas Tarpon Springs, FL
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 667
- Services billed
- 2,679
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 208 | 160 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 205 | 203 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 190 | 123 |
| Established patient office or other outpatient visit, 40-54 minutes | 151 | 118 |
| New patient office or other outpatient visit, 60-74 minutes | 90 | 90 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 71 | 71 |
| Needle measurement of electrical activity in arm or leg muscles, complete study | 67 | 64 |
| Established patient office or other outpatient visit, 20-29 minutes | 59 | 52 |
| Measurement of brain wave activity (eeg), awake and asleep | 55 | 53 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 53 | 48 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Donepezil Hcl Other prescribers in Holiday, FL | 129 |
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in Holiday, FL | 94 |
| Memantine Hcl Other prescribers in Holiday, FL | 86 |
| Levetiracetam Other prescribers in Holiday, FL | 52 |
| Aptiom (eslicarbazepine acetate) | 49 |
| Oxcarbazepine Other prescribers in Holiday, FL | 44 |
| Topiramate Other prescribers in Holiday, FL | 41 |
| Gamunex-C (immune globul g/gly/iga avg 46) | 40 |
| Primidone Other prescribers in Holiday, FL | 38 |
| Propranolol Hcl Other prescribers in Holiday, FL | 35 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 29 companies reported 154 payments worth $3,707 in total to this clinician.
| AbbVie Inc. | $673 |
|---|---|
| UCB, Inc. | $438 |
| Pfizer Inc. | $293 |
| Novartis Pharmaceuticals Corporation | $259 |
| Eisai Inc. | $258 |
| Tg Therapeutics, Inc. | $249 |
| Alexion Pharmaceuticals, Inc. | $190 |
| Sk Life Science, Inc. | $190 |
| Food and Beverage | $3,631 |
|---|---|
| Education | $76.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Dec 12, 2025 | Education in-kind | $76.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $194,731 in research payments for these studies, mostly to the institutions running them.
- A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease
Eli Lilly and Company · Completed · NCT06538116 - A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
Eli Lilly and Company · Active, not recruiting · NCT04437511 - Study name not reported
Novo Nordisk As
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.